Skip to main content

Table 5 Current clinical trials testing PS-specific antibodies in cancer patients

From: TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy

Intervention (mAb)

Primary target

Study

Conditions

Clinical trial

Identifier

Bavituximab

Temozolomide

Radiation

PS DNA (alkylating agent)

DNA (damaging energy)

Bavituximab with radiation in diagnosed glioblastoma

Glioblastoma

Phase 2 – not recruiting

NCT03139916

Bavituximab

Pembrolizumab

PS

PD-1

Patients with advanced hepatocellular carcinoma

Hepatocellular cancer

Phase 2 - recruiting

NCT03519997

Bavituximab

Pembrolizumab

PS

PD-1

Advanced Gastric Cancer after one prior standard therapy regimen

Gastric Cancer

Gastro-Esophageal Cancer

Phase 2 - recruiting

NCT04099641